|
| Status |
Public on Nov 20, 2012 |
| Title |
Rescue Of Dysfunctional Autophagy By Peptide IDR-1018 Attenuates Hyperinflammatory Phenotype Of Cystic Fibrosis Cells (RNA-seq) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Genome-wide gene expression was measured in peripheral blood mononuclear cells (PBMCs) from patients with cystic fibrosis (CF) after treatment in vitro with the flagellin protein fliC, and/or synthetic peptide IDR-1018 to assess patterns of gene expression.
The patterns of gene expression suggest that CF cells have a hyperinflammatory phenotype including dysfunctional autophagy processes. The synthetic peptide IDR-1018 attentuates this hyperinflammatory phenotype.
|
| |
|
| Overall design |
Total RNA was obtained from PBMCs obtained from CF patients after treatment with the fliC flagellin protein (that is known to play a role in CF lung inflammation), and/or the peptide IDR-1018 that has anti-inflammatory properties. Comparison of genes and pathways affected by these treatments indicated the role of autophagy process in CF disease.
|
| |
|
| Contributor(s) |
Mayer ML, Blohmke CJ, Falsafi R, Fjell CD, Madera L, Turvey SE, Hancock RE |
| Citation(s) |
23264659 |
| Submission date |
Jan 27, 2012 |
| Last update date |
May 15, 2019 |
| Contact name |
Christopher Fjell |
| E-mail(s) |
cfjell@mail.ubc.ca
|
| Organization name |
University of British Columbia
|
| Department |
Medicine
|
| Street address |
Room 166 - 1081 Burrard Street
|
| City |
Vancouver |
| State/province |
BC |
| ZIP/Postal code |
V6Z 1Y6 |
| Country |
Canada |
| |
|
| Platforms (1) |
| GPL10999 |
Illumina Genome Analyzer IIx (Homo sapiens) |
|
| Samples (17)
|
| GSM867278 |
Untreated PBMC-CF patient D1-2 |
| GSM867279 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2 |
| GSM867280 |
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D1-2 |
| GSM867281 |
Untreated PBMC-CF patient D-2 |
| GSM867282 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-2 |
| GSM867283 |
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-2 |
| GSM867284 |
Untreated PBMC-CF patient D-3 |
| GSM867285 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-3 |
| GSM867286 |
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-3 |
| GSM867287 |
Untreated PBMC-CF patient D-4 |
| GSM867288 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-4 |
| GSM867289 |
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-4 |
| GSM867290 |
Untreated PBMC-CF patient D-5 |
| GSM867291 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-5 |
| GSM867292 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-27 |
| GSM867293 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-32 |
| GSM867294 |
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-33 |
|
| Relations |
| SRA |
SRP010644 |
| BioProject |
PRJNA152699 |
Less...
More...